Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments
Ghashghaei S., Abbaszadeh M., Karimi S., Ataie-Fashtami L., Bajouri A., Vosough M.
Prospective Study on Hair & Scalp, published in Cell J (2023) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Cell J (2023)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 37038694
- PMCID
- PMC10105300
- DOI
- 10.22074/cellj.2023.557550.1067
- Citations
- 2
Abstract (original English)
Vitiligo is an auto-immune disease, causing depigmentation of skin in 0.2-1.8% of global population. Topical corticosteroids and calcineurin inhibitors are the only treatments with firm evidence of optimal effectiveness with considerable side effects. Phototherapies might not induce serious side effects, although the effectiveness of the method is limited. Advanced therapy medicinal products (ATMPs) are emerging treatment modalities based on correction and replacement of affected genes, damaged tissues or cells in treatment of difficult-to-treat diseases. Due to optimal effectiveness and minimal side effects, ATMPs have recently gained much attention in order to develop new treatments. In this review, the ATMPs for treating vitiligo were along with its clinical success, affordability and cost-effectiveness. Currently, the main ATMP based products using in treatment of vitiligo are non-cultured epidermal cell, melanocytes, and hair follicle melanocytes. These products have shown promising results in the non-responding vitiligo patients. Furthermore, mesenchymal stem cells and multi-lineage differentiating stress enduring cells are other new potential modalities. Recently, Iranian Food and Drug Administration (IR-FDA) authorized the first cell-based product for vitiligo. This product is autologous suspension of keratinocytes and melanocytes. Although ATMPs are efficient and could
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia.
Systematic Review with a reported sample of 724 on Hair Loss, Hair Regeneration, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
- n = 724
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
DKK3-CKAP4 signaling drives fibroimmune remodeling and hair follicle miniaturization in androgenetic alopecia
Meta-analysis on Hair Loss, Hair Regeneration, published in Theranostics (2026) — summary generated from the PubMed abstract.
- 2026
Theranostics - Level ASystematic ReviewEurope PMC
Autolougous platelet concentrates in esthetic medicine
Systematic Review on Scar, Skin Aging, Facial Rejuvenation, Hair Regeneration, published in Periodontol 2000 (2025) — summary generated from the PubMed abstract.
- 2025
Periodontol 200016 citations - Level ASystematic ReviewPubMed
The Potency of Adipose-Derived Mesenchymal Stem Cells to Increase Ovarian Function in Primary Ovarian Insufficiency: A Systematic Review of in vivo Studies.
Systematic Review with a reported sample of 5 on Hair & Scalp, published in Gynecol Obstet Invest (2025) — summary generated from the PubMed abstract.
- 2025
- n = 5
Gynecol Obstet Invest - Level ASystematic ReviewPubMed
Efficacy and safety of platelet-rich plasma therapy in systemic sclerosis and localized scleroderma; a systematic review.
Systematic Review on Hair Regeneration, published in Arch Dermatol Res (2025) — summary generated from the PubMed abstract.
- 2025
Arch Dermatol Res2 citations